Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q9H4B7
UPID:
TBB1_HUMAN
Alternative names:
-
Alternative UPACC:
Q9H4B7
Background:
Tubulin beta-1 chain, encoded by the gene with accession number Q9H4B7, plays a pivotal role in cell structure and function as the primary component of microtubules. These cylindrical structures, composed of alpha- and beta-tubulin heterodimers, are essential for various cellular processes including mitosis, intracellular transport, and the maintenance of cell shape.
Therapeutic significance:
The association of Tubulin beta-1 chain with Macrothrombocytopenia, an autosomal dominant blood disorder, underscores its clinical relevance. Understanding the role of Tubulin beta-1 chain could open doors to potential therapeutic strategies for treating this and possibly other related disorders.